Articles tagged with Cancer Patients
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.
A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.
A new scale called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale was found to be more effective at predicting frailty than conventional methods. The scale identifies high-risk medications linked to falls and fatigue, allowing oncology teams to deprescribe them and improve patients' overall health.
A recent study published in PLOS ONE found that opioid prescriptions declined for US patients with both cancer and non-cancer pain between 2012 and 2019. The proportion of people receiving any opioid prescription dropped from 49.7% to 30.5% for non-cancer pain and from 86.0% to 78.7% for cancer pain.
A recent study found that women with lung cancer experience significant changes in their sexual desire and vaginal pain/discomfort after diagnosis. The research highlights the need for addressing sexual health in thoracic oncology care to improve patients' quality of life and overall well-being.
A recent study published by Wiley suggests that biological sex differences are the primary reason for higher cancer rates in men compared to women. The study analyzed data from 171,274 males and 122,826 females aged 50-71 years and found that incidence was lower in men only for thyroid and gallbladder cancers.
Researchers have developed a proof-of-concept model that uses artificial intelligence to combine multiple types of data from different sources to predict patient outcomes. The models demonstrate the ability to make prognostic determinations while uncovering the predictive bases of features used to predict patient risk.
Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.
Researchers at Dartmouth Cancer Center developed a new approach for detecting and quantifying tumor heterogeneity in breast cancer. High levels of heterogeneity are linked to poor patient outcomes, while specific proteins regulate its extent. The study aims to utilize this approach in therapeutic decision-making.
The NCI-backed Molecular Targets Platform streamlines and catalyzes drug development by integrating pediatric cancer targets and pathways. This platform empowers researchers, pharmaceutical companies, and advocacy groups to accelerate the pace of drug development for pediatric cancer.
Researchers at Cedars-Sinai Cancer identified genetic signatures linked to patient response to immunotherapy in bladder and other cancers. High DDR1 expression is associated with 'cold' tumors, while high DDR2 is linked to 'hot' tumors.
A study found that cold temperatures activate brown adipose tissue that competes with tumors for glucose, inhibiting tumor growth and prolonging survival. Researchers suggest that cold therapy could be a promising approach to cancer therapy.
Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.
A new study by CU Anschutz researchers found that over 70% of breast cancer patients experience changes in their sexual health during and after treatment. Patients desire early education and counseling from medical teams to address these issues, which are often overlooked.
A recent JAMA study found a positive association between high insulin dosage and cancer incidence among patients with type 1 diabetes. The study suggests that clinicians may need to balance cancer risk when treating patients on high insulin doses, with improving insulin sensitivity potentially being a preferred approach.
A study investigated total and out-of-pocket costs of genetic counseling among commercially insured adults with cancer, finding that these costs can significantly impact patient care. Factors contributing to higher costs were identified, highlighting the need for more affordable genetic testing options.
A study found that a majority of online pharmacies selling imatinib, a chronic myeloid leukemia therapy, are uncertified and operate unsafely. Patients may face risks of nonadherence, treatment failures, and adverse events if they use these pharmacies.
A new study published in JAMA Oncology has found a significant association between daily insulin dose and increased cancer risk in patients with type 1 diabetes. The research, led by Yuanjie Mao, investigated the relationships between various risk factors and cancer incidence in this population.
Researchers discover gene AVIL responsible for deadly brain tumor also causes two forms of childhood cancer, rhabdomyosarcoma. Blocking AVIL activity prevents formation of the disease in lab samples and mouse models.
Researchers used Guardant NGS to analyze nearly 17,000 lung cancer samples and found MET amplification in 1.2% of cases, with 20.8% having overlapping oncogenic drivers. The study suggests that high gene copy numbers and smaller amplified regions can be used to enrich for the true MET-sensitive population.
Researchers at the University of Copenhagen have developed a new method to detect biliary tract cancer and other serious cancers by analyzing changes in microRNA molecules in patient blood. This approach enables early diagnosis and has potential for targeted treatments.
A combination of gemcitabine and docetaxel shows excellent outcomes in patients with high-risk non-muscle-invasive bladder cancer. The 'Gem/Doce' therapy provides a safe and effective alternative to BCG treatment, resulting in high response rates and good tolerability.
A study of over 500 patients with multiple myeloma reveals a high prevalence of genetic alterations in oncogenic pathways, leading to treatment resistance. The research found a specific link between RASopathies and mutations in these pathways, offering new insights into the development of resistance mechanisms.
A recent study published in CANCER highlights the growing concern among Hodgkin lymphoma survivors. The analysis found that individuals with early-stage HL are now at a higher risk of death from cardiovascular disease compared to cancer after approximately 60 and 120 months of follow-up. This indicates that more effective measures are ...
Researchers at Max Delbrück Center for Molecular Medicine found that silencing the EBAG9 gene in CAR T cells increases their effectiveness and reduces side effects. This breakthrough could lead to a new therapy approach for blood cancer patients.
Scientists from A*STAR and NUS Cancer Science Institute identified a key cancer progression mechanism that could lead to more effective treatments. The discovery involves reactivating the hTERT gene, which is responsible for prolonging telomeres in cancer cells.
A quality improvement project at Dartmouth Cancer Center increased serious illness conversations between patients and providers from 0% to 70%, reflecting the importance of early discussions on prognosis and treatment options. The project's success was attributed to standardized work, an engaged interdisciplinary team, and system-level...
A new study uses machine learning models to predict cancer patients' responses to immunotherapy based on their gut microbiome features. The research identifies common gut bacterial taxa associated with responders versus non-responders, providing a potential tool for distinguishing and predicting immunotherapy responders.
Researchers at the University of South Australia have discovered that combining anti-rejection medication with immune checkpoint inhibitors can significantly reduce the risk of organ rejection and eliminate cancer cells in a quarter of patients. The study involved 22 patients with renal transplants and incurable locally advanced or met...
A study of 5,329 US patients who died from medical aid found that well-educated, white patients with cancer dominated the group. The majority (72%) had some college education and nearly 75% had cancer.
A new study published in Blood Advances found that caregivers for people with multiple myeloma experience higher levels of anxiety and depression compared to the patients they support. The study also highlights a critical gap in communication between providers and caregivers regarding the terminal nature of the disease.
Researchers used radiomics-based machine learning models to detect pancreatic cancer on prediagnostic CT scans, identifying it up to 386 days before clinical diagnosis. The AI model showed high accuracy and specificity, with a range of 94-98%, and was unaffected by image variations.
Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.
A recent study published in CANCER found that adults with hematologic malignancies mounted immune responses after a COVID-19 booster dose, with 56% of nonresponders producing antibodies. However, the initial vaccine showed limited effectiveness, with only 48% of patients developing detectable antibodies.
A new machine learning model uses network-based biomarkers to predict patient response to immunotherapy in multiple cancer types, enabling personalized treatment plans. The study improves upon conventional methods, increasing accuracy and benefiting more patients.
A study of 720 patients with thoracic cancer found increased odds of unsuccessful telemedicine visits among Black and disadvantaged patients. Unsuccessful telemedicine visits were associated with worse clinical outcomes, highlighting the need for improved access to healthcare.
A recent study by Elizabeth Kessler, MD, found that older patients with advanced bladder cancer prioritize open communication with their care providers about treatment expectations and quality of life changes. The research also highlights the importance of involving families in care planning and aligning care with patients' core priori...
Researchers have found that high levels of iron can generate toxic free radicals, which damage lipids and ultimately lead to cell death. The team is exploring the use of compounds like JKE-1674 to induce ferroptosis in prostate cancer cells, making them more vulnerable to treatment.
Abemaciclib, a CDK4 & 6 inhibitor, showed profound inhibition of cell proliferation and triggered senescence and apoptosis in breast cancer cells. Continuous dosing provided sustained inhibition with irreversible effects through apoptosis, supporting the differentiated safety and efficacy profile.
Researchers have identified 42 genes related to 15 different cellular mechanisms that affect the risk of different types of somatic mutations. This comprehensive study may help explain cancer predisposition and potentially personalize prevention programs and cancer treatments.
A study using data from the Surveillance, Epidemiology, and End Results database found that married individuals had better survival prospects than divorced or widowed people. The researchers developed a nomogram to predict 3-5 year survivals, with marital status being one of several independent prognostic factors.
Researchers developed a nomogram to predict anal cancer risk in persons with HIV infection, highlighting increased risk among those living with the virus. The model estimates quantitative risk based on patient characteristics, informing screening decisions.
A new classification system for colorectal cancer has been proposed, grouping cancers into five subtypes based on epithelial status, microsatellite status, and fibrosis. This update could inform targeted drug development efforts and improve treatment approaches for patients with different biological characteristics.
This qualitative study provides consensus-level guidance to clinicians caring for patients with advanced cancer-related pain and opioid misuse or use disorder. The findings emphasize the importance of comprehensive assessment and multimodal treatment strategies.
Experts outline a framework for treating cancer pain in patients with opioid use disorder or prescription opioid misuse. The study highlights the need for better integration of addiction treatment in cancer care, particularly prescribing methadone and buprenorphine.
A systematic review and meta-analysis of 52 studies found that electronic noses can accurately detect volatile organic compounds in exhaled breath for cancer diagnosis. The diagnostic accuracy varied across studies, with some showing high sensitivity and specificity.
Researchers at Johns Hopkins Kimmel Cancer Center developed a targeted immunotoxin that delivers into breast ducts, eliminating visible and invisible precancerous lesions in laboratory studies. The treatment showed strong cancer-killing effects in all cell lines and was well-tolerated in mouse models.
A new study found that COVID-19 vaccines are safe and effective for patients treated for lung cancer with immune checkpoint inhibitors. However, the vaccine's immunogenicity was lower in these patients, raising concerns that require further evaluation.
A population-based study found that patients with estrogen receptor-positive breast cancer who experienced hot flashes while on adjuvant hormone therapy had worse outcomes and a higher risk of early treatment discontinuation. The study suggests that managing side effects may not be enough to prevent treatment discontinuation, highlight...
A Phase II study published in Frontiers in Oncology found that daily use of AHCC supplementation may help most patients eliminate their HPV infection and decrease the risk of HPV-related cancers. The study showed that 14 of 22 patients (63.6%) became HPV-negative, suggesting a potential treatment option for persistent HPV infections.
A recent study found that lower-income and less-educated patients, particularly those from racial/ethnic minorities, have a higher likelihood of being diagnosed with advanced lung cancer. The association between socioeconomic status and lung cancer stage at diagnosis was observed across different ethnicities, healthcare facilities, and...
Researchers at Cedars-Sinai Cancer have identified a novel immune checkpoint pathway that could lead to better understanding and treatment of hepatocellular carcinoma. The study suggests that blocking this pathway, combined with immunotherapy, may provide a new therapeutic strategy for liver cancer.
Researchers identified a three-gene signature in multiple myeloma tumors that predicts a positive response to selinexor-based therapy. The discovery could improve patient selection for targeted agents and expand the use of the drug into patients who haven't failed other therapies.
A recent scientific review suggests that the oral microbiome may hold key answers to pancreatic cancer development, diagnosis, and treatment. The study found a distinct association between oral microbiome patterns and pancreatic tumors, with certain disease-driving bacteria identified in both.
The COVID-19 pandemic significantly impacted patient accruals in oncology clinical trials, with a 46% decline early on. However, the recovery has been progressive, with newly activated clinical trials increasing by 467 from 2019 to June 2021.
African countries face a growing cancer burden, with an estimated 2.1 million new cases and 1.4 million related deaths expected by 2040. Insufficient healthcare resources and infrastructure will likely overwhelm capacity levels, delaying screenings and limiting treatment options if action is not taken.
A recent study found that certain bacteria species in the gut are associated with a higher risk of colorectal cancer in younger populations. The research suggests that dietary patterns high in processed meats, low-calorie drinks, and liquor may contribute to this increased risk.
A new HIFU treatment approach, MR-guided focused ultrasound (MRgFUS), effectively controlled disease in patients with intermediate-risk prostate cancer, reducing adverse side effects. The procedure is less invasive, taking about two hours, and results in minimal recovery time.
The COVID-19 pandemic caused a substantial disruption to cancer clinical trials in the US, with a 46% decrease in new patient accruals and a 24% decrease in newly activated trials between March and May 2020. However, both patient accruals and trial activations have gradually recovered since then.